PERBEDAAN KADAR LEUKOSIT, HEMOGLOBIN, DAN TROMBOSIT PASIEN LEUKEMIA MYELOID KRONIS SEBELUM DAN SESUDAH MENDAPAT TERAPI HYDROXYUREA DAN NILOTINIB SELAMA TIGA BULAN DI RSUD DR. MOEWARDI

Eau Sagrim, Marcelina (2017) PERBEDAAN KADAR LEUKOSIT, HEMOGLOBIN, DAN TROMBOSIT PASIEN LEUKEMIA MYELOID KRONIS SEBELUM DAN SESUDAH MENDAPAT TERAPI HYDROXYUREA DAN NILOTINIB SELAMA TIGA BULAN DI RSUD DR. MOEWARDI. Other thesis, Universitas Sebelas Maret.

[img] PDF - Published Version
Download (353Kb)

    Abstract

    Background: Chronic Myeloid Leukemia (CML) is caused by the BCR – ABL tyrosine kinase , the product of the Philadelphia chromosome. Standart the therapy in patients cml historically is Hydroxyurea. Hydroxyurea is chemotherapy given in patients to control hematology. Currently there are treatnent for CML, that is targeted theraphy. Now the recommendation for the first line CML theraphy is Nilotinib because showed the high response with low risk than hydroxyurea. This research aims to tell the difference of Leukocytes , Hb and Platelets in patients CML get treatment Hydroxyurea and Nilotinib in RSUD Dr. Moewardi. Methods: The research by design cohort retrospective , in patients cml who are therapy Hydroxyurea and Nilotinib the period 2015 - 2016 .Data taken from the record medical obtained in the record medical RSUD Dr Moewardi in june - july 2017 .The data collected covering characteristic subject ( age , sex ) , and the leukocytes , hemoglobin and platelets before and after get therapy Hydroxyurea and Nilotinib .Data analyzed use test t to data normally distributed or test Mann Whitney for data not normally distributed to compare data before and after therapy . And analysis chi square to know relations between two variable through the spss 20 for windows. Results: Sample data 80 medical record data . Value levels of Hb between patients with nilotinib therapy and therapeutic hydroxyurea there is no significant difference ( p = 0,156 ) , Levels of leukocytes there are significant differences ( p = 0.010 ) , levels of platelets there are no significant differences ( p = 0,312 ). Conclusions: There is a significant difference between the patients CML get therapy hydroxyurea and nilotinib. Keywords: CML, Hydroxyurea, Nilotinib, Leukocytes, Haemoglobin, Platelet

    Item Type: Thesis (Other)
    Subjects: R Medicine > R Medicine (General)
    Divisions: Fakultas Kedokteran
    Depositing User: Indrawan indra
    Date Deposited: 21 Nov 2017 17:32
    Last Modified: 21 Nov 2017 17:32
    URI: https://eprints.uns.ac.id/id/eprint/36119

    Actions (login required)

    View Item